Skip to main content

Table 1 Prevalence of anti-MAP Abs and MAP DNA among CD, UC and nIBD patients

From: Mycobacterium avium subsp. paratuberculosis and associated risk factors for inflammatory bowel disease in Iranian patients

Diagnosis

anti-MAP1

Abs+

anti-MAP1

Abs−

anti-MAP2

Abs+

anti-MAP2

Abs−

IS900+

IS900−

CD

13 (46%)

15 (54%)

11 (39%)

17 (61%)

18 (64%)

10 (36%)

UC

1 (3%)

29 (97%)

5 (16.7%)

25 (83.3%)

10 (33%)

20 (67%)

nIBD

3 (5%)

59 (95%)

4 (6%)

58 (94%)

7 (9.7%)

55 (90.3%)

  1. Numbers with the relative percentages of subjects positive (Abs+) and negative (Abs−) to MAP3865c133–141 (MAP1) and MAP3865c125–133 (MAP2) peptides. Analogous data referred to detection of MAP-specific IS900 gene is provided for each group
Back to article page

Gut Pathogens

ISSN: 1757-4749